Replies to post #5086 on Jaguar Health Inc (JAGX)

[oldstocks]

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
4/8/2024 8:30am

Top line results forthcoming for company's phase
3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX). ("Jaguar" or the
"Company") today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq) has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before August 13, 2024.
"We are pleased to have obtained additional time from Nasdaq to evidence compliance with the bid price requirement," said Lisa Conte, Jaguar's president and CEO. "As reported on February 23, 2024, Jaguar requested a hearing to appeal a potential delisting of the Company's securities from Nasdaq, and a hearing was scheduled. Because we have been granted the additional grace period, this hearing will no longer occur."
Jaguar's paramount near-term clinical activity is the Company's Phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea. Top line results from this pivotal study are forthcoming.

[RichieBoy]

I was trying to understand why company would
use same biostatistician. Wouldn't you fire the guy for the sake of your own company's reputation.

Something simply wasn't adding up, still isn't truth be told...